Core Points - Onconetix, Inc. received a Staff delisting letter from Nasdaq due to failure to file its Annual Report on Form 10-K for the fiscal year ended December 30, 2024, violating Nasdaq's continued listing requirements [1] - The company is already under review for non-compliance with the Minimum Bid Price Rule, having failed to maintain a minimum bid price of $1.00 per share from November 25, 2024, to January 10, 2025 [3] - Onconetix intends to file the Form 10-K promptly to regain compliance with Nasdaq rules [3] Company Overview - Onconetix is a commercial stage biotechnology company focused on men's health and oncology solutions [4] - The company owns Proclarix®, an in vitro diagnostic test for prostate cancer, and ENTADFI, an FDA-approved treatment for benign prostatic hyperplasia [4]
Onconetix, Inc. Announces Receipt of Additional Notice from Nasdaq